[ad_1]
Townsquare Capital LLC bought a new position in Natera, Inc. (NASDAQ:NTRA – Free Report) during the fourth quarter, Holdings Channel reports. The institutional investor bought 1,568 shares of the medical research company’s stock, valued at approximately $248,000.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Blue Trust Inc. raised its position in shares of Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after purchasing an additional 97 shares during the period. Versant Capital Management Inc increased its position in Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after buying an additional 166 shares during the period. EverSource Wealth Advisors LLC increased its position in Natera by 372.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock worth $52,000 after buying an additional 261 shares during the period. Principal Securities Inc. lifted its stake in Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock valued at $54,000 after buying an additional 59 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC boosted its holdings in shares of Natera by 1,328.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company’s stock valued at $57,000 after acquiring an additional 332 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.
Insider Transactions at Natera
In other news, CFO Michael Burkes Brophy sold 946 shares of the company’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $171.98, for a total transaction of $162,693.08. Following the completion of the sale, the chief financial officer now owns 109,474 shares in the company, valued at approximately $18,827,338.52. This represents a 0.86 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Solomon Moshkevich sold 5,201 shares of the stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $165.87, for a total value of $862,689.87. Following the transaction, the insider now directly owns 135,483 shares in the company, valued at approximately $22,472,565.21. This represents a 3.70 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 198,584 shares of company stock worth $30,557,738 in the last 90 days. 7.60% of the stock is owned by insiders.
Natera Price Performance
NTRA opened at $144.62 on Wednesday. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 1 year low of $87.20 and a 1 year high of $183.00. The stock has a fifty day moving average price of $149.13 and a 200 day moving average price of $153.04. The stock has a market cap of $19.55 billion, a price-to-earnings ratio of -82.17 and a beta of 1.80.
Natera (NASDAQ:NTRA – Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.01. The business had revenue of $476.10 million during the quarter, compared to analysts’ expectations of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.
Analyst Ratings Changes
Several brokerages recently weighed in on NTRA. Sanford C. Bernstein lifted their price objective on shares of Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a research report on Friday, January 10th. StockNews.com raised Natera from a “sell” rating to a “hold” rating in a report on Wednesday, March 19th. Robert W. Baird increased their price objective on Natera from $183.00 to $188.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. BTIG Research reiterated a “buy” rating on shares of Natera in a research report on Friday, February 28th. Finally, Barclays cut their price objective on shares of Natera from $200.00 to $160.00 and set an “overweight” rating on the stock in a research note on Thursday, April 10th. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, Natera has a consensus rating of “Moderate Buy” and an average price target of $175.76.
Read Our Latest Stock Report on Natera
Natera Company Profile
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Featured Stories
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).
Receive News & Ratings for Natera Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Natera and related companies with MarketBeat.com’s FREE daily email newsletter.
[ad_2]
Source link